申请人:——
公开号:US20020040060A1
公开(公告)日:2002-04-04
The invention relates to compounds of the formula
1
wherein
R is hydrogen, lower alkyl, lower alkoxy, halogen, amino, —N(R
6
)
2
or trifluoromethyl;
R
1
is hydrogen, lower alkoxy or halogen;
R and R
1
may be together —CH═CH—CH═CH—;
R
2
is halogen, lower alkyl or trifluoromethyl;
R
3
is hydrogen or lower alkyl;
R
4
is hydrogen or a cyclic tertiary amine, optionally substituted by lower alkyl;
R
5
is hydrogen, nitro, amino or —N(R
6
)
2
;
R
6
is hydrogen or lower alkyl;
X is —C(O)N(R
6
)—, —(CH
2
)
n
O—, —(CH
2
)—,—N(R
6
)—, —N(R
6
)C(O)— or —N(R
6
)(CH
2
)
n
—; and
n is I or 2;
and pharmaceutically acceptable acid addition salts thereof.
The compounds of formula I may be used for the treatment of diseases related to the NK-l receptor.
本发明涉及化合物公式1,其中R为氢、低级烷基、低级烷氧基、卤素、氨基、-N(R6)2或三氟甲基;R1为氢、低级烷氧基或卤素;R和R1可以结合成-CH═CH-CH═CH-;R2为卤素、低级烷基或三氟甲基;R3为氢或低级烷基;R4为氢或环状三级胺,可选择地被低级烷基取代;R5为氢、硝基、氨基或-N(R6)2;R6为氢或低级烷基;X为-C(O)N(R6)-、-(CH2)nO-、-(CH2)-、-N(R6)-、-N(R6)C(O)-或-N(R6)(CH2)n-;n为1或2;以及其药学上可接受的酸加盐。公式I的化合物可用于治疗与NK-l受体相关的疾病。